anti-HA-1/HLA-A2 TCR T cell therapy (Leiden University Medical Center)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-HA-1/HLA-A2 TCR T cell therapy (Leiden University Medical Center)
Drug Alias NameTCR-transduced T-cell immunotherapy (LUMC)anti-HA-2 TCR T cell therapy (Leiden University Medical Center)T-cell receptor-transduced virus specific T-cells immunotherapy (Leiden University Medical Center)
ClassificationBiologics > Protein drugs > Recombinant proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionHLA Class I Histocompatibility Antigen, A-2 alpha Chain modulatorsMinor Histocompatibility Protein HA-1 modulators
TargetsMinor Histocompatibility Protein HA-1HLA Class I Histocompatibility Antigen, A-2 alpha Chain
Therapy Area/IndicationsHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesLeiden University Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLeiden University Medical Center
Active IndicationsN/A
Inactive IndicationsHematologic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A